Palladium One Mining Inc. (NKORF)(PDM:CA) – Tyko Drilling Program Yielding Exciting Results

Wednesday, January 06, 2021

Palladium One Mining Inc. (NKORF)(PDM:CA)
Tyko Drilling Program Yielding Exciting Results

Noble Capital Markets research on Palladium One Mining is published under ticker symbols (NKORF and PDM:CA). The price target is in USD and based on ticker symbol NKORF. Palladium One Mining Inc is a palladium dominant, PGE, nickel, copper exploration and development company. Its assets consist of the Lantinen Koillismaa and Kostonjarvi PGE-Cu-Ni projects, located in north-central Finland and the Tyko Ni-Cu-PGE and Disraeli PGE-Ni-Cu properties in Ontario, Canada. LK is targeting disseminated sulphide along 38 kilometers of favorable basal contact. The KS project is targeting massive sulphide within a 20,000-hectare land package covering a regional scale gravity and magnetic geophysical anomaly. Tyko is a 13,000-hectare project targeting disseminated and massive sulphide in a highly metamorphosed Archean terrain. Disraeli is a 2,500-hectare project targeting PGE-rich disseminated and massive sulphide in a highly productive Proterozoic mid-continent rift.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initial results are encouraging. The first two holes of the 2020 Tyko drill program yielded exciting results. Hole TH-20-016 returned 8.7% nickel equivalent (6.6% nickel, 3.7% copper, and 1.5 grams per tonne of platinum group elements) over 3.8 meters at less than 30 meters true depth at the Smoke Lake target. Note that 8.7% nickel equivalent equates to ~193 pounds per tonne. Based on current nickel prices of $7.87/pound, the results have positive implications for in situ value potential. Hole TK-20-015 returned 4.8% nickel equivalent (3.9% nickel, 1.4% copper, and 0.8 grams per tonne of platinum group elements) from 30 meters down hole.

    Assay results still pending.  Palladium One commenced diamond drilling of the Smoke Lake electromagnetic anomaly in late November. High-resolution drone-based magnetic and ground-based horizontal loop electromagnetic surveys, undertaken shortly before drilling, refined the anomaly resulting in the discovery of massive magmatic sulphides. All 13 holes drilled at Smoke Lake intersected magmatic …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

How Good are Experts at Predicting the Market?

 


Last Year’s Market Predictions – What was the Final Batting Average?

 

Here’s a look back to see how the experts’ projections stood up in the topsy turvy year of 2020. We unearthed a December 19, 2019 article on Yahoo by Emily McCormick that highlighted the 2020 predictions of 23 Wall Street strategists. Each provided a target for the S&P 500 for the year ending 2020, along with additional commentary. The majority of the reports were issued in the first two weeks of December 2019. The data and comments we are citing come directly from that article.

What Actually Occurred

Before we get into the observations, we would note the S&P 500 closed at 3,230.78 on December 31, 2019. It closed higher at 3,756.07 on December 31, 2020. That’s a 16.2% annual return. Obviously, that return masks a wild intra-year ride, as the S&P 500 bottomed out on March 23 at 2,191 (intra-day) and closed the day at 2,237.40. For those investors with perfect timing, the S&P 500 rose 71.6% from its March 23 lows to the end of 2020.

Forecasts

In mid-December 2019, the average of the 23 estimates for the 2020 closing S&P 500 index was 3,332, off by nearly 13% relative to what the actual closing level was in 2020. Obviously, COVID and all its implications were not factored into the prognosticators’ forecasts. The range of forecasts went from 3,000, implying a down year in 2020, to as high as 3,600, which was still more than 4% below the S&P 500’s actual performance. The 3,600 prediction was a true outlier as the next closest estimate was 3,450. If we looked at a distribution of the forecasts, nine of the 23 were below the 3,332 average.

So, in the year of wild market swings, impacted by a 100-year pandemic, the experts were clearly off by a significant factor.

There were recurring themes within the commentary from the strategists as to what could impact the stock market in 2020. As one would expect, the election, China/U.S. relations, especially as related to trade, and an accommodative Federal Reserve were mentioned prominently by most strategists.

Forecasts vs. Actual

But some of the other predictions did not play-out as well. For example, in assembling their forecast, most of the strategists predicted higher earnings for the S&P 500. In fact, many of the projections for S&P 500 earnings were in the $165-$175 range; when fully reported, earnings are actually expected to have dropped year-over-year to the $135 level from $163 in 2019.

Some strategists favored non-U.S. markets, predicting better returns overseas. But according to Yardeni Research, the MSCI Share price index for the U.S. was up 19.2% in 2020, well above the All Country Index of 14.3%. And in fact, the U.S. market outperformed each of the five other indexes: European Market, Japan, U.K., and Emerging Markets. To be fair, the Asian Emerging Market significantly outperformed the U.S., but the overall Emerging Markets average was held back by poor performance in Latin America.

Another prediction raised was a move from Growth stocks to Value stocks. This switch does not appear to have happened as much of the upswing in the Index was driven by the growth-oriented FAANGM stocks during much of the year.

One interesting prediction that seems to have come true was by
Julian Emanuel of BTIG, who stated that with “zero-fee online trading, 2020 could be the year the public falls in love with stocks again.” The rise of Robinhood seems to agree with this statement.

Take-Away

It is often said, with good reason, that it is easier to predict the stock market when given a longer time horizon, perhaps even ten years or longer. The reason is the smoothing that the impact of time and average growth has on the outlier years. Predicting what will happen tomorrow involves so many unknown influences that “experts” are befuddled by the exercise daily.

The predictions made in 2019 concerning the earnings of the S&P 500 were off in terms of direction (earnings were down, not up). This would cause one to expect lower stock prices than predicted. Obviously this didn’t happen either.  While knowledge and understanding of what market strategist predictions are is a useful guide to our own risk/reward assessments, it’s helpful to remember as we enter the new year and new sets of market predictions that the stock market is like a talented major league pitcher – they’re able to get even the most gifted hitters out more often than not.  Yet, we can still improve our own skills by observing the big bats go up against them. 

 

Suggested Reading:

Investment of Excess Corporate Cash

The Expected Pace of the IPO Market in 2021

What do Investors Look At?

 

Are you subscribed to Channelchek’s active YouTube channel?

 

Sources:

Emily McCormick/Yahoo Finance 12/19 Article

 

NobleCon17 Presenting Companies List

NobleCon17 Presenting Company Schedule
January 19 & 20, 2021

Complete rebroadcast catalog now available on Channelchek!

Two days of public companies presenting, followed by Q&A sessions moderated by accredited research analysts. Four panels featuring key opinion leaders. Virtual Networking. For more information on NobleCon17, go to nobleconference.com.

   

Click the logos to view advanced market data and recent news for each company
All times listed are Eastern Standard Time

Tuesday January 19, 2021


Healthcare Panel
Track 1 – 8:35am
 

Transportation Panel
Track 2 – 8:35am
 

XBIO (Nasdaq)
Track 1 – 9:45am
 

OS Therapies
Track 2 – 9:45am
 

ENCUF (OTCQB)
Track 3 – 9:45am
Watch the Preview

GLVMF (OTCQX)
Track 4 – 9:45am
Watch the Preview

CLBS (Nasdaq)
Track 1 – 10:30am
Watch the Preview

III (Nasdaq)
Track 2 – 10:30am
Watch the Preview

IPOOF (OTCQX)
Track 3 – 10:30am
Watch the Preview

UUUU (NYSE)
Track 4 – 10:30am
 

HSDT (Nasdaq)
Track 1 – 11:15am
Watch the Preview

OSS (Nasdaq)
Track 2 – 11:15am
Watch the Preview

GEVO (Nasdaq)
Track 3 – 11:15am
Watch the Preview

ELYGF (OTCQX)
Track 4 – 11:15am
Watch the Preview

LCTX (NYSE)
Track 1 – 12:00pm
Watch the Preview

ORN (NYSE)
Track 2 – 12:00pm
 

CPST (Nasdaq)
Track 3 – 12:00pm
Watch the Preview

EXK (NYSE)
Track 4 – 12:00pm
Watch the Preview

Currently Scheduling
Track 1 – 12:45pm
 

LMB (Nasdaq)
Track 2 – 12:45pm
Watch the Preview

INDO (NYSE)
Track 3 – 12:45pm
Watch the Preview

SMTS (NYSE)
Track 4 – 12:45pm
Watch the Preview

CTXR (Nasdaq)
Track 1 – 1:30pm
 

CMTL (NasdaqGS)
Track 2 – 1:30pm
 

CMLS (Nasdaq)
Track 3 – 1:30pm
 

AUIAF (OTCQB)
Track 4 – 1:30pm
Watch the Preview

COCP (Nasdaq)
Track 1 – 2:15pm
Watch the Preview

REKR (Nasdaq)
Track 2 – 2:15pm
Watch the Preview

TPCO (Nasdaq)
Track 3 – 2:15pm
 

AUXXF (OTCQX)
Track 4 – 2:15pm
Watch the Preview

CURR (OTCQB)
Track 1 – 3:00pm
 

TAALF (OTCQX)
Track 2 – 3:00pm
Watch the Preview

Playboy Enterprises
Track 3 – 3:00pm
Watch the Preview

CHKKF (OTCQB)
Track 4 – 3:00pm
Watch the Preview

GNPX (Nasdaq)
Track 1 – 3:45pm
Watch the Preview

FLYLF (OTCQX)
Track 2 – 3:45pm
 

EVC (NYSE)
Track 3 – 3:45pm
 

NTGSF (OTCQX)
Track 4 – 3:45pm
Watch the Preview

JAGX (Nasdaq)
Track 1 – 4:30pm
Watch the Preview

JETMF (OTCQB)
Track 2 – 4:30pm
Watch the Preview

TSQ (NYSE)
Track 3 – 4:30pm
 

NRGOF (OTCQB)
Track 4 – 4:30pm
Watch the Preview

RCAR (OTCPK)
Track 1 – 5:15pm
 

PANL (Nasdaq)
Track 2 – 5:15pm
 
 
Natural Resources Panel
Track 4 – 5:15pm

Wednesday January 20, 2021


ELDN (Nasdaq)
Track 1 – 9:00am
 

PTPI (Nasdaq)
Track 2 – 9:00am
 

MEEC (OTCQB)
Track 3 – 9:00am
 

NMGRF (OTCQX)
Track 4 – 9:00am
 

VIVXF (OTCQB)
Track 1 – 9:45am
Watch the Preview

MIND (NasdaqGS)
Track 2 – 9:45am
Watch the Preview

SSP (NasdaqGS)
Track 3 – 9:45am
 

NKORF (OTCPK)
Track 4 – 9:45am
Watch the Preview

OCGN (Nasdaq)
Track 1 – 10:30am
Watch the Preview

GNK (NYSE)
Track 2 – 10:30am
 

ACCO (NYSE)
Track 3 – 10:30am
 

LODE (NYSE)
Track 4 – 10:30am
Watch the Preview

CRPOF (OTCQX)
Track 1 – 11:15am
 

INSW (NYSE)
Track 2 – 11:15am
 

DLHC (Nasdaq)
Track 3 – 11:15am
Watch the Preview

MUNMF (OTCQB)
Track 4 – 11:15am
Watch the Preview

AEZS (Nasdaq)
Track 1 – 12:00pm
 

GLDD (NasdaqGS)
Track 2 – 12:00pm
Watch the Preview

GMBL (Nasdaq)
Track 3 – 12:00pm
Watch the Preview

STTDF (OTCQB)
Track 4 – 12:00pm
Watch the Preview

KRBP (Nasdaq)
Track 1 – 12:45pm
Watch the Preview

SHIP (Nasdaq)
Track 2 – 12:45pm
Watch the Preview

Private Company
Track 3 – 12:45pm
Watch the Preview

JAGGF (OTCPK)
Track 4 – 12:45pm
Watch the Preview

AYLA (Nasdaq)
Track 1 – 1:30pm
 

PXS (Nasdaq)
Track 2 – 1:30pm
 

FAT (Nasdaq)
Track 3 – 1:30pm
Watch the Preview

VGZ (NYSE)
Track 4 – 1:30pm
Watch the Preview

STMH (OTCQX)
Track 1 – 2:15pm
 

EGLE (NasdaqGS)
Track 2 – 2:15pm
Watch the Preview

SALM (Nasdaq)
Track 3 – 2:15pm
Watch the Preview

GLDRF (OTCQB)
Track 4 – 2:15pm
Watch the Preview

VNRX (NYSE)
Track 1 – 3:00pm
 

EDRY (Nasdaq)
Track 2 – 3:00pm
 

VYGVF (OTCQB)
Track 3 – 3:00pm
Watch the Preview

GGIFF (OTC)
Track 4 – 3:00pm
 

Adaptive Phage
Track 1 – 3:45pm
 

NXTTF (OTCQB)
Track 2 – 3:45pm
Watch the Preview

LSYN (OTCQB)
Track 3 – 3:45pm
 

FTK (NYSE)
Track 4 – 3:45pm
 

ONTX (Nasdaq)
Track 1 – 4:30pm
Watch the Preview

CXW (NYSE)
Track 2 – 4:30pm
 

GTBAF (BUSXF)
Track 3 – 4:30pm
 

GTBAF (OTCQX)
Track 4 – 4:30pm
 
 
ESEA (Nasdaq)
Track 2 – 5:15pm
 
 
Track 4 – 5:15pm

InvestorBrandNetwork is the Media Sponsor of NobleCon
InvestorWire is the Official NewsWire of NobleCon

Release – Sigyn Therapeutics (SIGY) – Reports Results of Pilot Study to Address Inflammatory CytoVesicles

 


Sigyn Therapeutics™ Reports Results of Pilot Study to Address Inflammatory CytoVesicles

 

Sigyn Therapy™ is a Candidate to Treat Life-Threatening Inflammatory Conditions That Are Not Addressed with Drug Therapies

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company whose focus is the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy™ to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream.

Cytokine Storm Syndrome is an excessive response of the immune system that is induced by infectious and non-infectious conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or uncontrolled release of pro-inflammatory cytokines, which can lead to multiple organ failure and cause death. The annual market opportunity to address Cytokine Storm related indications exceeds $20 billion and includes sepsis, the most common cause of hospital deaths worldwide. Virus-induced Cytokine Storm Syndrome is a leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.

Sigyn Therapy is a proprietary blood purification technology designed to overcome the limitations of previous drug and device candidates to treat acute inflammatory conditions. Incorporated within Sigyn Therapy is a cocktail of adsorbent components with unique binding and capture characteristics to optimize the broad-spectrum depletion of inflammatory targets from the bloodstream. These targets include pro-inflammatory cytokines, endotoxin and CytoVesicles (extracellular vesicles that transport inflammatory cytokine cargos) that participate in concert with freely circulating cytokines to further escalate the Cytokine Storm. CytoVesicles are an important yet previously elusive target as they can be 20-60 times larger than cytokines themselves.

In the in vitro pilot study, 104nm liposomes were utilized as a model system to assess the ability of Sigyn Therapy’s adsorbent components to deplete CytoVesicles from human blood plasma. After a two-hour interaction with Sigyn’s adsorbent components, liposome concentrations in human blood plasma were reduced ~90%. Previously published studies have validated liposomes as a model for the isolation of extracellular vesicles from blood based on the similarity of their size and structural characteristics.

“When we designed Sigyn Therapy, we envisioned a device that could be broadly deployed by the medical community, yet also have expansive first-in-industry capabilities that offer to improve patient outcomes,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics. “When considering our previous report that Sigyn Therapy™ clears both endotoxin and inflammatory cytokines from human blood plasma, the observation from our CytoVesicle pilot study further reinforces the potential for our vision to become a therapeutic reality.”

Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines already located in hospitals and clinics worldwide. On December 1, 2020, the Company reported the results of an in vitro study that validated the ability of Sigyn Therapy to simultaneously reduce the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock. The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.

An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy. Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.

The resulting data from each of these studies will be incorporated into an Investigational Device Exemption (IDE) that Sigyn Therapeutics plans to submit to the United States Food and Drug Administration (FDA) in 2021.

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

Contact Sigyn Therapeutics, Inc.

Jim Joyce
Chairman, CEO
(619) 368-2000
jj@sigyntherapeutics.com

Source: Sigyn Therapeutics, Inc.

Energy Services of America (ESOA) – FY2020 Earnings Revised Higher Due to Stimulus Legislation

Wednesday, January 06, 2021

Energy Services of America (ESOA)
FY2020 Earnings Revised Higher Due to Stimulus Legislation

Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is primarily engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical and automotive industries, and does incidental work such as water and sewer projects. Energy Service’s other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services and other services related to pipeline construction.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Fiscal 2020 (September) results were revised upward due to stimulus legislation. The reported net FY2020 loss of $0.039/share was revised upward to net income of $0.123/share in the FY2020 10-K filed yesterday. More clarity on the taxation of PPP loan forgiveness included in the stimulus legislation resulted in the reversal of $2.7 million of the reported tax provision. There was no change to adjusted FY2020 EBITDA of $8.0 million.

    Closing of WV Pipeline acquisition adds confidence to FY2021 EBITDA estimate of $10.8 million.  EBITDA growth in the 30% range reflects the strong finish to FY2020, sustained higher profitability due to the shift in the business model and the closing of the WV Pipeline acquisition last week. Forecasted revenue of $122.5 million is a slight 3% improvement from FY2020 revenue of $119.2 million and …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Caladrius Biosciences (CLBS) Scheduled To Present at NobleCon17


Join Caladrius Biosciences (CLBS) CEO David Mazzo, Ph.D. at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join David to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

InPlay Oil (IPOOF)(IPO:CA) Scheduled To Present at NobleCon17


Join InPlay Oil (IPOOF)(IPO:CA) CEO Doug Bartole at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join Doug to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

Newrange Gold (NRGOF)(NRG:CA) Scheduled To Present at NobleCon17


Join Newrange Gold (NRGOF)(NRG:CA) CEO Robert Archer at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join Robert to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

MIND Technology (MIND) Scheduled To Present at NobleCon17


Join MIND Technology (MIND) CEO/CFO Robert Capps & COO Dennis Morris at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join Robert and Dennis to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

Kiromic BioPharma (KRBP) Scheduled To Present at NobleCon17


Join Kiromic BioPharma (KRBP) CEO Maurizio Chiriva-Internati & CFO Tony Tontat at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join Maurizio and Tony to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

Gevo, Inc. (GEVO) – Two milestones in a week – FEED Engineering firm identified

Tuesday, January 05, 2021

Gevo, Inc. (GEVO)
Two milestones in a week – FEED Engineering firm identified

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment and the Gevo Development/Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of isobutanol, including the development of its biocatalysts, the production and sale of biojet fuel, its Retrofit process and the next generation of chemicals and biofuels that will be based on its isobutanol technology. Gevo Development/Agri-Energy is the key revenue generating segment which involves the operation of the Luverne Facility and production of ethanol, isobutanol and related products.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Another milestone hit with identification of FEED firm. Koch Project Solutions, LLC is performing front end engineering, design and project execution management services (FEED) for the renewable fuel expansion projects. Koch Project Solutions is part of a subsidiary of Koch Industries. Like Trafigura, the new relationship could open up collaboration opportunities on other fronts. While there is no indication that other subs are involved, establishing a relationship with a major energy industry player should be viewed as a positive development.

    Debt free milestone hit.  Strong December stock price performance was catalyst for debt conversion into equity. Last week, we learned from an ATM equity prospectus update that all of the convert debt was converted into equity. A total of 5.67 million shares were issued to Whitebox, and ~$14 million of cash was preserved to keep current cash near $79 million …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Ayala Pharmaceuticals (AYLA) – Pivotal Desmoid Tumor Trial is Set to Initiate in H1 2021

Tuesday, January 05, 2021

Ayala Pharmaceuticals (AYLA)
Pivotal Desmoid Tumor Trial is Set to Initiate in H1 2021

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company’s current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ayala receives the green light to proceed with a Phase 2/3 pivotal study for desmoid tumor. Yesterday, Ayala announced that the U.S. Food and Drug Administration (FDA) agreed to allow Ayala to proceed with a Phase 2/3 study, which can potentially be a registration-enabling pivotal trial, evaluating AL102 for the treatment of desmoid tumors.

    What is next?.  The company intends to commence Phase 2/3 RINGSIDE study in adult and adolescent patients with desmoid tumors in H1 2021. RINGSIDE study will include two parts: Part 1 to enroll 36 patients assessing 3 doses of AL102 and Part 2 to use a double-blind placebo-controlled section enrolling up to 156 patients. The interim data read-out from Part 1 and dose selection is expected by …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Industry Report – Energy – 2020-4Q Review and Outlook

Tuesday, January 5, 2021

Energy Industry Report

Energy 2020-4Q Review and Outlook

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

  • Oil prices rose sharply beginning in November but are still well below levels at the start of the year. Oil prices continued to rebound from the sharp drop seen in the first quarter as investor enthusiasm about a Coronavirus vaccine pushed prices higher. WTI oil prices began the quarter in the mid thirties and finished the quarter near $47.50/BBL. Near-month oil futures prices are locked in a narrow range near current spot prices. Prices are still well below beginning-of-the-year prices near $60 per barrel.
  • Natural gas prices had risen but have fallen in recent weeks due to warm weather. Natural Gas prices also rose during the quarter although they have slipped in recent weeks. Recent weakness reflects significantly warmer-than-normal weather. Population-weighted heating degree days were 21% warmer than the 10-year trailing average in the month of November and similar to historical averages in December. As a result of warm weather, natural gas in storage ended the year at all-time high levels for this time of year and 2.6% above the trailing five-year average.
  • Energy stocks climbed 27% in the quarter mirroring the performance of oil prices. Energy stocks, as measured by the XLE Energy Index, rose alongside oil prices climbing 27% during the quarter. The rise began in November when oil prices rose. Even with the strong performance in the fourth quarter, however, the energy index was down 38% in 2020. This compares to a 14% rise in the overall market.
  • The near-term outlook for energy stocks has improved but we still have long-term concerns. The rebound in oil prices came faster than expected. We have been adjusting our models to reflect higher prices but are maintaining our long-term oil price forecast of $50 per barrel and $2.50 per mcf. Our near-term outlook for energy stocks has improved. We expect companies to report favorable results for the next few quarters unless rising production pushes energy prices lower. Longer-term, we have concern that oil demand will be constrained by power generation competition from renewable energy and decreased demand for gasoline and diesel due to a growth in electric vehicles. At the same time, supply pressure from an increasingly active OPEC and continued drilling productivity will mean lower energy prices.

Oil Prices

Oil prices continued to rebound from the sharp drop seen in the first quarter as investor enthusiasm about a Coronavirus vaccine pushed prices higher. WTI prices began the quarter in the mid thirties and finished the quarter near $47.50/BBL. Near-month oil futures prices are locked in a narrow range near current spot prices. Prices are still well below beginning-of-the-year prices near $60 per barrel. Interestingly, drilling had not resumed by the end of the year. Baker Hughes reported 351 active rigs in the United States as of December 31, less than half the number from a year ago. Consequently, domestic production has not changed. The U.S. Energy Information Administration (EIA) reports that domestic oil production rose a modest 2.7% between September and November (the last month available) and attributes the increase largely to hurricane-disrupted wells coming back online. We would expect to see production expand in upcoming months with increased drilling.

Natural Gas Prices 

Natural Gas prices also rose during the quarter although they have slipped in recent weeks. Recent weakness reflects significantly warmer-than-normal weather. Population-weighted heating degree days were 21% warmer than the 10-year trailing average in the month of November and similar to historical averages in December. As a result of warm weather, natural gas in storage ended the year at all-time high levels for this time of year and 2.6% above the trailing five-year average. Natural gas futures prices show prices rising modestly as the futures curve extends into the spring.


Energy Stocks 

Energy stocks, as measured by the XLE Energy Index, rose alongside oil prices climbing 27% during the quarter. The chart below shows that the strength in energy stocks began in November, the exact time that oil prices began to rise. The performance in the quarter far outpaced the overall market. Even with the strong performance in the fourth quarter, however, the energy index was down 38% in 2020. This compares to a 14% rise in the overall market.


Outlook 

The rebound in oil prices came faster than expected. We have been adjusting our models to reflect higher prices but are maintaining our long-term oil price forecast of $50 per barrel and $2.50 per mcf. Energy companies should start reporting positive cash flow at these prices and increasing drilling budgets. That said, marginal wells will most likely not be drilled, and production growth will be difficult unless we see prices rise back to a level near $60/bbl. and $3.00/mcf.  Companies must continue to work to lower costs to adjust to current prices by finetuning drilling techniques. 

Our near-term outlook for energy stocks has improved. We expect companies to report favorable results for the next few quarters unless rising production pushes energy prices lower. Longer-term, we have concern that oil demand will be constrained by power generation competition from renewable energy and decreased demand for gasoline and diesel due to a growth in electric vehicles. At the same time, supply pressure from an increasingly active OPEC and continued drilling productivity will mean lower energy prices. We recommend investors stay focused on energy companies with solid balance sheets, low operating costs and protected prices.

 

GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc. (“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.

IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.

The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.

Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and noninvestment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months.

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Senior Equity Analyst focusing on energy and utility stocks. 24 years of experience as an analyst. Chartered Financial Analyst©. MBA from Washington University in St. Louis and BA in Economics from Carleton College in Minnesota. Named WSJ ‘Best on the Street’ Analyst four times. Named Forbes/StarMine’s “Best Brokerage Analyst” three times. FINRA licenses 7, 63, 86, 87.

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to by an investment advisor, that advisor may receive a benefit in respect of transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by . This report may not be reproduced, distributed or published for any purpose unless authorized by.

RESEARCH ANALYST CERTIFICATION

Independence Of View

All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation

No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.

Ownership and Material Conflicts of Interest

Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

NOBLE RATINGS DEFINITIONS % OF SECURITIES COVERED % IB CLIENTS
Outperform: potential return is >15% above the current price 78% 34%
Market Perform: potential return is -15% to 15% of the current price 5% 1%
Underperform: potential return is >15% below the current price 0% 0%

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same.

Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.

Noble Capital Markets, Inc.
225 NE Mizner Blvd. Suite 150
Boca Raton, FL 33432
561-994-1191

Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.
Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.
Member – SIPC (Securities Investor Protection Corporation)

Report ID: 11924